NCT05480267 is a NA clinical trial of surgical treatment for lumbar spondylolisthesis in Lumbar Spondylolisthesis, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT05480267?

NCT05480267 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT05480267?

Interventions in NCT05480267: surgical treatment for lumbar spondylolisthesis.

What condition does NCT05480267 study?

NCT05480267 studies Lumbar Spondylolisthesis, Unilateral Biportal Endoscopy, Minimally Invasive Technique, Surgical Treatment.

Is NCT05480267 still recruiting?

NCT05480267 is currently status unknown. Last updated 29 July 2022.

Last reviewed 2022-07-29 · How we verify

NCT05480267

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A RCT of UBE vs. MIS-TLIF in Lumbar Spondylolisthesis

Status unknown NA Last updated 29 July 2022

What this trial tests

NA trial testing surgical treatment for lumbar spondylolisthesis in Lumbar Spondylolisthesis in 340 participants. Status unknown.

Timeline

1 September 2022

Primary endpoint
1 May 2025

1 September 2025

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	340
Start date	1 September 2022
Primary completion	1 May 2025
Estimated completion	1 September 2025

Drugs / interventions tested

surgical treatment for lumbar spondylolisthesis

Conditions studied

Lumbar Spondylolisthesis — all drugs for Lumbar Spondylolisthesis →
Unilateral Biportal Endoscopy — all drugs for Unilateral Biportal Endoscopy →
Minimally Invasive Technique — all drugs for Minimally Invasive Technique →
Surgical Treatment — all drugs for Surgical Treatment →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 40 to 75, any sex, with Lumbar Spondylolisthesis or Unilateral Biportal Endoscopy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Unilateral biportal endoscopy (UBE) is a new spinal minimally invasive technique improved for the treatment of lumbar spondylolisthesis (LSP). The present study aims to establish a multicenter, large sample, randomized controlled study to explore the technical advantages and surgical indications of this new technique in the treatment of LSP by comparing with the classical minimally invasive posterior spinal interbody fusion; to compare the postoperative clinical and imaging results and analyze the surgical complications and preventive measures.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Endoscopic Spine Surgery: A Scoping Review of the Literature.
Mulhall D, Kow CY, Veilleux C, Oliveira Masson A, et al · · 2026 · PMID 41806368 · DOI 10.1177/21925682261434579

Verify or expand the search:

Other recruiting trials for Lumbar Spondylolisthesis

Currently open trials in the same condition.

NCT05029726 — Regional Anesthesia in Minimally Invasive Lumbar Spine Surgery · Phase 4 · recruiting
NCT05945550 — Comparison of Complication Rates Between Initial and Re-operative Anterior Lumbar Interbody Fusion Surgery: Is There a D · active not recruiting
NCT03570801 — SLIP II Registry: Spinal Laminectomy Versus Instrumented Pedicle Screw Fusion · NA · active not recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05480267 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 29 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05480267.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing